Related Experiment Video
Updated: Jul 24, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
13.7K
Plasmablastic lymphoma: current knowledge and future directions
Ji-Wei Li1, Hong-Ling Peng2, Xiao-Yan Zhou3,4,5
1Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Frontiers in Immunology
|February 28, 2024
Summary
Plasmablastic lymphoma (PBL) is an aggressive cancer. This review summarizes current knowledge on PBL, including its features, molecular profile, and treatment strategies for better patient outcomes.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Plasmablastic lymphoma (PBL) is an aggressive non-Hodgkin lymphoma.
- PBL is strongly associated with HIV infection and immunodeficiency but also occurs in immunocompetent individuals.
- PBL exhibits distinct clinical, pathological, and molecular features.
Purpose of the Study:
- To review the epidemiology of PBL.
- To summarize clinical, pathological, and molecular features of PBL.
- To discuss diagnostic and therapeutic strategies for PBL.
Main Methods:
- Literature review of studies on Plasmablastic lymphoma.
- Analysis of clinical and pathological data.
- Review of molecular profiling studies, including gene expression analysis.
Main Results:
- PBL shows plasmablastic morphology and plasma cell marker expression.
- Clinicopathologic features differ between HIV-positive and HIV-negative patients.
- Frequent c-MYC rearrangement and BCR signaling pathway downregulation are key molecular findings.
Conclusions:
- PBL is an aggressive lymphoma with unique characteristics.
- Understanding molecular features aids in diagnosis and treatment.
- Despite advances, PBL prognosis remains poor, necessitating novel therapeutic approaches.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...